Mercury Laboratories Ltd
Mercury Laboratories Ltd Live Price Chart
Performance
| Previous Close | ₹ |
| High | ₹ |
| Volume | 13 |
| 52W Range | ₹ - ₹ |
| Open | ₹ |
| Low | ₹ |
| Market Cap | ₹ 105 Cr |
Mercury Laboratories Ltd Technicals
| 20 Day | ₹ 796.153 |
| 50 Day | ₹ 806.692 |
| 100 Day | ₹ 821.029 |
| 200 Day | ₹ 838.975 |
| 20 Day | ₹ 800.363 |
| 50 Day | ₹ 803.857 |
| 100 Day | ₹ 829.568 |
| 200 Day | ₹ 840.198 |
Mercury Laboratories Ltd Fundamentals
| ROCE | 11.490 |
| P/E Ratio | 19.850 |
| P/B Ratio | 1.680 |
| Industry P/E | 1.680 |
| Debt to Equity | 39.117 |
| ROE | 8.813 |
| EPS | 39.320 |
| Dividend Yield | 0.450 |
| Book Value | 464.653 |
| Face Value | 10.000 |
Mercury Laboratories Ltd Financials
| Particulars | Y202503 | Y202403 | Y202303 | Y202203 | Y202103 |
|---|---|---|---|---|---|
| Total Revenue | 76.1699 | 76.6475 | 77.053 | 58.7397 | 69.4817 |
| Total Expenses | 71.5082 | 69.7272 | 69.6084 | 53.8328 | 61.5727 |
| Profit After Tax | 3.1449 | 5.6542 | 5.5788 | 3.5619 | 5.3375 |
Mercury Laboratories Ltd Shareholding Pattern
| Promoter Holdings | 73.658 % |
| FIIs | 0.000 % |
| DIIs | 0.000 % |
| MutualFund | 0.000 % |
| Retail | 16.587 % |
| Others - | 9.755 % |
About Mercury Laboratories Ltd
Mercury Laboratories Limited, the registered partnership firm started its business activity in year 1962. Subsequently, it converted into Private Limited Company & incorporated in February, 1982. Later, it converted into Limited Company in 1992 in Maharashtra. The Company has obtained ISO 9001:2008 registrations. It is engaged into the manufacturing and export of wide range of Pharmaceutical items. The Company products have been in Gynae and Pediatrics Segment. It is mainly dedicated to Mother & Child Healthcare. Two new products launched in Ergacap Division in 2012-13. The Company introduced new drugs such as Teclobet, Tanolite, Clinzit, Clinzita-A, Levotryl Tablet, Levotryl-M Tablet, Levotryl Syrup, THA-4, THA-8, Pyloryl, Pangs At, Feveryl Drops, Feveryl Suspension in its Mother Child Care specialized segment. It further established Institutional Business with Govt. Institutions, Semi Government and Hospitals & Clinics in 2014-15. The Company launched new world class GMP facility for all its liquids and tablets conforming requirement of WHO in 2015-16. It also has increased the manufacturing capacity for tablets and liquids in 2023-24. ...
